HC Wainwright Reaffirms “Buy” Rating for Krystal Biotech (NASDAQ:KRYS)

Krystal Biotech (NASDAQ:KRYS)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $221.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 19.85% from the stock’s current price.

Several other brokerages also recently issued reports on KRYS. Stifel Nicolaus boosted their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. William Blair raised Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Citigroup increased their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, Evercore ISI boosted their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Krystal Biotech has an average rating of “Buy” and an average target price of $202.29.

Krystal Biotech Trading Down 0.5 %

Shares of KRYS opened at $184.40 on Tuesday. Krystal Biotech has a 52 week low of $103.83 and a 52 week high of $219.34. The firm has a market cap of $5.30 billion, a price-to-earnings ratio of 104.18 and a beta of 0.80. The stock has a 50 day moving average of $181.31 and a 200-day moving average of $184.78.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The company had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company’s revenue for the quarter was up 879.9% on a year-over-year basis. During the same period last year, the firm posted ($0.67) EPS. On average, sell-side analysts predict that Krystal Biotech will post 2.97 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now directly owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This trade represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 14.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Street Corp grew its holdings in shares of Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after buying an additional 119,936 shares in the last quarter. Geode Capital Management LLC boosted its position in Krystal Biotech by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock worth $107,714,000 after acquiring an additional 11,411 shares during the period. Dimensional Fund Advisors LP grew its stake in Krystal Biotech by 1.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 580,452 shares of the company’s stock valued at $106,593,000 after acquiring an additional 7,537 shares in the last quarter. Hood River Capital Management LLC increased its holdings in shares of Krystal Biotech by 5.1% in the 2nd quarter. Hood River Capital Management LLC now owns 521,093 shares of the company’s stock valued at $95,694,000 after purchasing an additional 25,507 shares during the period. Finally, Franklin Resources Inc. lifted its position in shares of Krystal Biotech by 34.2% in the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after purchasing an additional 62,178 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).